Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanobiotix S.A. ADR
(NQ:
NBTX
)
5.280
+0.350 (+7.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
Next >
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
October 23, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
October 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
September 29, 2023
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix S.A. (NASDAQ: NBTX) Leading the Way in Monday Trading Based on Percentage Gain
July 10, 2023
Via
Investor Brand Network
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1
October 04, 2023
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
September 28, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
September 26, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
September 19, 2023
Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
September 13, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
September 05, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
August 15, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
August 04, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
July 20, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
July 19, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
July 10, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
June 08, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
May 17, 2023
Reported €30.2 million in cash and cash equivalents as of March 31, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
May 05, 2023
Company agreed to term sheet as of May 3, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
April 24, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
April 17, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 11, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
March 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
March 14, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 14, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
December 27, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
December 21, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.